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Thalidomide Ameliorates Cisplatin-Induced Nephrotoxicity
by Inhibiting Renal Inflammation in an Experimental Model
Keyvan Amirshahrokhi1,3 and Ali-Reza Khalili2
ABSTRACT—Cisplatin is a platinum-based chemotherapy drug. However, its chemotherapeutic use is
restricted by serious side effects, especially nephrotoxicity. Inflammatory mechanisms have a significant
role in the pathogenesis of cisplatin-induced nephrotoxicity. Thalidomide is an immunomodulatory and
anti-inflammatory agent and is used for the treatment of various inflammatory diseases. The purpose of
this study was to investigate the potential nephroprotective effect of thalidomide in a mouse model of
cisplatin-induced nephrotoxicity. Nephrotoxicity was induced in mice by a single injection of cisplatin
(15 mg/kg, i.p.) and treated with thalidomide (50 and 100 mg/kg/day, orally) for 4 days, beginning 24 h
prior to the cisplatin injection. Renal toxicity induced by cisplatin was demonstrated by increasing pl-
asma levels of creatinine and blood urea nitrogen (BUN). Cisplatin increased the renal production of the
proinflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and transforming
growth factor (TGF)-β1. In addition, kidney levels of malondialdehyde (MDA), myeloperoxidase (M-
PO), and nitric oxide (NO) were increased by cisplatin. Biochemical results showed that thalidomide
reduced cisplatin-induced increase in plasma creatinine and BUN. Thalidomide treatment also signifi-
cantly reduced tissue levels of the proinflammatory cytokines, MDA, MPO, and NO and increased anti-
inflammatory cytokine IL-10. Furthermore, histological examination indicated that thalidomide ame-
liorated renal damage caused by cisplatin. These data suggest that thalidomide attenuates cisplatin-in-
duced nephrotoxicity possibly by inhibition of inflammatory reactions. Taken together, our findings i-
ndicate that thalidomide might be a valuable candidate for the prevention of nephrotoxicity in patients
receiving cisplatin.
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INTRODUCTION
Cisplatin (cis-diamminedichloroplatinum [II]) and
other platinum-containing compounds are important che-
motherapeutic agents, which have been used in the treat-
ment of various types of solid tumors, including nonsmall
cell and small cell lung cancer; esophageal, gastric, and
colon cancer; head and neck cancer; and genitourinary
cancers, particularly ovarian, testicular, and bladder cancer
[1]. The clinical use of cisplatin is often limited by its
undesirable side effects. Nephrotoxicity is the most impor-
tant and dose-limiting adverse effect of cisplatin which
occurs in 20–30 % of patients [2]. Although there is no
effective treatment for cisplatin-induced nephrotoxicity,
there are various anti-inflammatory, antioxidant, and
antiapoptotic agents that have been suggested to prevent
cisplatin nephrotoxicity [3]. Amifostine, a thiophosphate
cytoprotective agent, is approved by FDA to prevent kid-
ney damage caused by cisplatin, but is not commonly used
[4, 5]. The study of the pathogenesis of cisplatin nephro-
toxicity is important for the development of new therapeu-
tic strategies to reduce renal toxicity of cisplatin. The exact
mechanisms involved in cisplatin-induced renal dysfunc-
tion are not completely understood.
Several molecular mechanisms have been proposed
to be involved in the pathogenesis of cisplatin-induced
nephrotoxicity such as inflammation, oxidative stress,
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